We are live on ! Find out more
VOR icon

Vor Biopharma
VOR

68 hedge funds and large institutions have $140M invested in Vor Biopharma in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,700% more call options, than puts

Call options by funds: $38K | Put options by funds: $1K

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

13% more funds holding

Funds holding: 60 → 68 (+8)

4% more capital invested

Capital invested by funds: $134M → $140M (+$5.21M)

0.08% less ownership

Funds ownership: 4.41% → 4.32% (-0.08%)

5% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 20

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
68
Holders Change
+8
Holders Change %
+13.33%
% of All Funds
0.98%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
11
Increased
19
Reduced
20
Closed
2
Calls
$38K
Puts
$1K
Net Calls
+$37K
Net Calls Change
+$29K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$621K
2
Millennium Management
Millennium Management
New York
+$348K
3
ETC
Exchange Traded Concepts
Oklahoma
+$207K
4
Marshall Wace
Marshall Wace
United Kingdom
+$168K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$152K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$2.96M
2
Morgan Stanley
Morgan Stanley
New York
-$477K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$81.2K
4
BCM
Bridgeway Capital Management
Texas
-$65.9K
5
Bank of America
Bank of America
North Carolina
-$54.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$53.9M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$18M -$23.1K -525 -0.1%
PBA
3
Paradigm Biocapital Advisors
New York
$15.3M – – –
5VM
4
5AM Venture Management
California
$15.1M – – –
LCM
5
Laurion Capital Management
New York
$7.54M – – –
BlackRock
6
BlackRock
New York
$5.33M -$8.69K -198 -0.2%
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.3M +$152K +3,472 +4%
WP
8
Woodline Partners
California
$2.63M – – –
JJ
9
Johnson & Johnson
New Jersey
$2.55M – – –
AG
10
Artal Group
Luxembourg
$2.37M -$2.96M -67,371 -57%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.99M +$103K +2,357 +6%
State Street
12
State Street
Massachusetts
$1.56M +$109K +2,485 +8%
SCM
13
Sarissa Capital Management
Connecticut
$1.46M – – –
Northern Trust
14
Northern Trust
Illinois
$944K +$2.5K +57 +0.3%
MCM
15
MAI Capital Management
Ohio
$867K +$19.1K +435 +2%
Ensign Peak Advisors
16
Ensign Peak Advisors
Utah
$820K – – –
Renaissance Technologies
17
Renaissance Technologies
New York
$793K +$621K +14,153 +549%
Millennium Management
18
Millennium Management
New York
$375K +$348K +7,920 New
ETC
19
Exchange Traded Concepts
Oklahoma
$366K +$207K +4,713 +157%
BCM
20
Bridgeway Capital Management
Texas
$314K -$65.9K -1,500 -18%
Morgan Stanley
21
Morgan Stanley
New York
$300K -$477K -10,871 -63%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$248K -$7.99K -182 -3%
Charles Schwab
23
Charles Schwab
California
$246K – – –
Goldman Sachs
24
Goldman Sachs
New York
$221K +$120K +2,742 +143%
Marshall Wace
25
Marshall Wace
United Kingdom
$181K +$168K +3,816 New
1
2 3

VOR Hedge Fund Activity: Q1 2024 in Review

68 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q1 2024, worth a combined $140M — up 3.9% from $134M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new VOR positions and 2 closed out — a net gain of 9 holders — while 19 added to existing stakes and 20 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $621K. The largest seller was Artal Group, cutting an estimated $2.96M.

  • 68 institutional investors held Vor Biopharma (VOR) as of Q1 2024, up from 60 in Q4 2023.
  • Funds reported $140M of Vor Biopharma stock for Q1 2024, up 3.9% quarter-over-quarter.
  • 11 funds opened new Vor Biopharma positions in Q1 2024 and 2 closed out, a net change of +9 holders.
  • The largest Vor Biopharma buyer in Q1 2024 was Renaissance Technologies, an estimated $621K added.
  • The largest Vor Biopharma seller in Q1 2024 was Artal Group, an estimated $2.96M sold.

Based on aggregated 13F filings for Q1 2024.